Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
Volatility and Risk
Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Earnings and Valuation
This table compares Madrigal Pharmaceuticals and Rani Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $958.40 million | 13.18 | -$288.28 million | ($12.89) | -42.41 |
| Rani Therapeutics | $1.63 million | 71.84 | -$29.67 million | ($0.27) | -3.11 |
Rani Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for Madrigal Pharmaceuticals and Rani Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 2 | 15 | 0 | 2.78 |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Madrigal Pharmaceuticals currently has a consensus target price of $699.64, suggesting a potential upside of 27.99%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 941.67%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Madrigal Pharmaceuticals.
Profitability
This table compares Madrigal Pharmaceuticals and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -25.32% | -56.65% | -25.53% |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
Institutional and Insider Ownership
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Rani Therapeutics beats Madrigal Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
